Budesonide/formoterol for the treatment of asthma

Bibliography

• WORLD HEALTH ORGANIZATION (WHO): Bronchial asthma. Geneva, Switzerland (2000). WHO fact sheet No. 206.
   Google Scholar
• WEISS KB, SULLIVAN SD, LYTTLE CS: Trends in the cost of illness for asthma in the United States, 1985-1994.J. Allergy Clin. Immunol (2000) 106:493–499.
   PubMed Web of Science ®Google Scholar
• NATIONAL ASTHMA CAMPAIGN ASTHMA AUDIT: Out in the open. A true picture of asthma in the United Kingdom today. Asthma (2001) 6 (Suppl.) :11.
   Google Scholar
• WEISSFLOG D, MATTHYS H, VIRCHOW JC Jr: Epidemiology and costs of bronchial asthma and chronic bronchitis in Germany. Dtsch. Med. Wochenschc (2001) 126:803–808.
   PubMedGoogle Scholar
• GIBSON PG, POWELL H, COUGHLAN J et al.: Self-management education and regular practitioner review for adults with asthma. The Cochrane Library Issue 1. Update Software, Oxford (2003).
   Google Scholar
• NATIONAL INSTITUTES OF HEALTH: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE: Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health: National Heart, Lung, and Blood Institute, Bethesda (Report No. NIH-NHLI 02–3659) (2002).
   Google Scholar
• ••The most widely used guidelines for themanagement of asthma. They include definitions of asthma severity, recommend treatment options for maintenance and exacerbations and detail the goals of asthma therapy.
   Google Scholar
• BRITISH THORACIC SOCIETY: British guidelines on the management of asthma. Thorax (2003) 58\(Suppl. 1):1–94.
   Google Scholar
• ••These are the most recent guidelines for themanagement of asthma.
   Google Scholar
• BATEMAN ED, BOUSQUET J, BRAUNSTEIN GL: Is overall asthma control being achieved? A hypothesis-generating study. Ear: Respic J. (2001) 17:589–595.
   PubMed Web of Science ®Google Scholar
• BATEMAN ED, FRITH LF, BRAUNSTEIN GL: Achieving guideline-based asthma control: does the patient benefit? Ear: Respic (2002) 20:588–595.
   Google Scholar
• RABE KF, VERMEIRE PA, SORIANO JB, MAIER WC: Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Respic (2000) 16:802–807.
   PubMed Web of Science ®Google Scholar
• ••Results of a survey that highlights howcurrent asthma treatment fails to come close to the standards recommended in international treatment guidelines.
   Google Scholar
• STAHL E: Respiratory patients opinion survey (RESPONSE): market research from asthma patients in Europe. Am. J. Respic Crit. Care Med. (2002) 165:A109.
   Google Scholar
• STAHL E, HYLAND ME: Unmet needs of asthma patients, and how these are reflected in attitudes to the disease and its treatment. Respic (2002) 20\(Suppl. 38):410s.
   Google Scholar
• MORK A-C, VAN GANSE E, OSMAN L et al.: Factors affecting adherence to prescribed asthma treatment. Ear: Respic (2002) 20\(Suppl. 38):580.
   Google Scholar
• CHAPMAN KR, WALKER L, CLULEY S, FABBRI L: Improving patient compliance with asthma therapy. Respic Med (2000) 94:2–9.
   PubMed Web of Science ®Google Scholar
• CLARK NM, PARTRIDGE MR: Strengthening asthma education to enhance disease control. Chest (2002) 121:1661–1669.
   PubMed Web of Science ®Google Scholar
• WARNER JO, NASPITZ CK: Third international pediatric consensus statement on the management of childhood asthma. International Pediatric Consensus Group. Pediatr. Pulmonol (1998) 25:1–17.
   PubMed Web of Science ®Google Scholar
• GREENING AP, IND PW, NORTHFIELD M, SHAW G: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet (1994) 344:219–224.
   PubMed Web of Science ®Google Scholar
• ••A pivotal study demonstrating that addinga long-acting 132-agonist, salmeterol, to bedomethasone therapy provided superior asthma control compared with bedomethasone alone.
   Google Scholar
• PAUWELS RA, LOFDAHL CG, POSTMA DA et al.: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl. I Med. (1997) 337:1405–1411.
   Google Scholar
• ••A key study demonstrating the superiorefficacy of budesonide and formoterol in reducing the risk of exacerbations compared with budesonide alone.
   Google Scholar
• O'BYRNE PM, BARNES PJ, RODRIGUEZ-ROISIN R et al.: Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomised trial. Am. I Respic Grit. Care Med. (2001) 164(8 Pt 1):1392–1397.
   Google Scholar
• ••This study demonstrates the addedbenefits of adding formoterol to budesonide therapy.
   Google Scholar
• KIPS JC, O'CONNOR J, INMAN MD, SVENSON K, PAUWELS RA, O'BYRNE PM: A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am. I Respir. Crit. Care Med. (2000) 161:996–1001.
   PubMedGoogle Scholar
• PRICE D, DUTCHMAN D, MAWSON A, BODALIA B, DUGGAN S, TODD P: Early asthma control and maintenance with formoterol following reduction of inhaled corticosteroid dose. Thorax (2002) 57:791–798.
   PubMed Web of Science ®Google Scholar
• LINDBLAD T, MALMQVIST GRANLUND K, ROLLWAGE U, TROFAST E: Delivery characteristics of Symbicort Turbuhaler containing both budesonide and formoterol. Am. J. Respir. Crit. Care Med. (2001) 163:A863.
   Google Scholar
• AGERTOFT L, PEDERSEN S: Importance of training for correct Turbuhaler use in preschool children. Acta Paediatr. (1998) 87:842–847.
   PubMed Web of Science ®Google Scholar
• STAHL E, RIBEIRO LB, SANDAHL G: Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler in children with mild to moderate asthma. Pedlar. Pulmona (1996) 22:106–110.
   PubMedGoogle Scholar
• ASKING L: AstraZeneca industrial session: dry powder inhaler formulations for combination products: in vitro performance of combination products. J. Aerosol. Med. (2001) 14:502.
   Google Scholar
• HVIZDOS KM, JARVIS B: Budesonide inhalation suspension. A review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs (2000) 60:1141–1178.
   Google Scholar
• BARTOW RA, BROGDEN RN: Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs (1998) 55:303–322.
   Google Scholar
• OLIVIERI D, CHETTA A, DEL DONNO M et al: Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am. J. Respir. Grit. Care Med. (1997) 155:1864–1871.
   PubMed Web of Science ®Google Scholar
• VLIAGOFTIS H, SCHWINGSHACKL A,MILNE CD et al.: Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. I Allergy Clin. Immuna (2000) 106:537–545.
   Google Scholar
• MILLER-LARSSON A, JANSSON P, RUNSTROM A, BRATTSAND R: Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am. .1. Respir. Crit. Care Med. (2000) 162(4 Pt 1):1455–1461.
   Google Scholar
• •This paper provides evidence of, and a rationale for, the long duration of action of budesonide.
   Google Scholar
• BUSSE WW, CHERVINSKY P, CONDEMI J et al.: Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. I Allergy Clin. Immuna (1998) 101:457–463.
   PubMed Web of Science ®Google Scholar
• ••Evidence for the dose-response relationshipof budesonide.
   Google Scholar
• JATAKANON A, KHARITONOV S, LIM S, BARNES PJ: Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax (1999) 54:108–114.
   PubMed Web of Science ®Google Scholar
• PEDERSEN S, HANSEN OR: Budesonide treatment of moderate and severe asthma in children: a dose-response study. J. Allergy Clin. Immuna (1995) 95:29–33.
   PubMed Web of Science ®Google Scholar
• JONES AH, LANGDON CG, LEE PS et al: Pulmicort® Turbohaler® once daily as initial prophylactic therapy for asthma. Respir. Med. (1994) 88:293–299.
   PubMed Web of Science ®Google Scholar
• MCFADDEN ER, CASALE TB, EDWARDS TB et al.: Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma. J. Allergy Clin. Immunol (1999) 104:46–52.
   PubMed Web of Science ®Google Scholar
• SHAPIRO GG, MENDELSON LM, PEARLMAN DS: Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids. Ann. Allergy Asthma Immuna (2001) 86:633–640.
   PubMedGoogle Scholar
• RINGDAL N, DEROM E, WAHLIN-BOLL E, PAUWELS R: Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir. Med. (1998) 92:1017–1021.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates the dose-responserelationship of formoterol.
   Google Scholar
• SEBEROVA E, ANDERSON A: Oxis® (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir. Med. (2000) 94:607–611.
   PubMed Web of Science ®Google Scholar
• PALMQVIST M, PERSSON G, LAZER L, ROSENBORG J, LARSSON P, LOTVALL J: Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Ear: Respir J. (1997) 10:2484–2489.
   PubMed Web of Science ®Google Scholar
• PALMQVIST M, ARVISSON P, BECKMAN 0, PETERSON S, LOTVALL J: Onset of bronchodilation of budesonide/formoterol versus salmeterol/fluticasone in single inhalers. Pulm. Pharmaca Ther. (2001) 14:29–34.
   PubMed Web of Science ®Google Scholar
• •Evidence for the rapid and sustained effect of budesonide/formoterol compared with fluticasone propionate/salmeterol.
   Google Scholar
• GRONNEROD TA, VON BERG A, SCHWABE G, SOLIMAN S: Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir. Med. (2000) 94:661–667.
   PubMed Web of Science ®Google Scholar
• EKSTROM T, RINGDAL N, TUKIAINEN P, RUNNERSTROM E, SOLIMAN S: A 3-month comparison of formoterol with terbutaline via Turbuhaler. A placebo-controlled study. Ann. Allergy Asthma Immuna (1998) 81:225–230.
   PubMed Web of Science ®Google Scholar
• EKSTROM T, RINGDAL N, SOBRADILLO V, RUNNERSTROM E, SOLIMAN S: Low-dose formoterol Turbuhaler (ads) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.). Respir. Med. (1998) 92:1040–1045.
   Google Scholar
• BARNES PJ: Effect of P-agonists on inflammatory cells. I Allergy Clin. Immuna (1999) 104:S10–S17.
   Google Scholar
• KORN SH, JERRE A, BRATTSAND R: Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Ear: Respir J. (2001) 17:1070–1077.
   PubMed Web of Science ®Google Scholar
• SPOELSTRA FM, POSTMA DS, HOVENGA H, NOORDHOEK JA, KAUFFMAN HF: Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax (2002) 57:237–241.
   PubMed Web of Science ®Google Scholar
• ZETTERSTROM 0, BUHL R, MELLEM H et al.: Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Ear: Respir J. (2001) 18:261–268.
   Google Scholar
• ••The first study to compare the efficacy andtolerability of budesonide/formoterol with that of the monocomponents budesonide and formoterol delivered via separate inhalers and budesonide alone.
   Google Scholar
• AGGARWAL SK, FRITH LJ, HO M et al.: Fluticasone propionate/salmeterol delivered from a single inhaler demonstrates synergistic benefits in asthma. Am. J. Respir. Crit. Care Med. (2003) 167:A890.
   Google Scholar
• TAYLOR DR, HANCOX RJ: Interactions between corticosteroids and 13-agonists. Thorax (2000) 55:595–602.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: Scientific rationale for inhaled combination therapy with long-acting f12-agonists and corticosteroids. Eur. Respir: J. (2002) 19:182-191. A comprehensive review of the evidence supporting the superior efficacy of a combination of inhaled corticosteroids and long-acting 132-agonists.
   Google Scholar
• MAK JC, NISHIKAWA M, BARNES PJ: Glucocorticoids increase 132-adrenergic receptor transcription in human lung. Am. J. Physiol (1995) 268(1 Pt 1):L41–L46.
   Google Scholar
• BARANIUK JM, ALT M, BRODY D et al.: Glucocorticoids induce 132-adrenergic receptor function in human nasal mucosa. Am. J. Respir. Grit. Care Med. (1997) 155:704–710.
   PubMed Web of Science ®Google Scholar
• •This paper suggests an explanation for the proposed synergy between corticosteroids and 132-agonists.
   Google Scholar
• ROTH M, JOHNSON PRA, RUDIGERJJ et al.: Interaction between glucocorticoids and 132-agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet (2002) 360:1293–1299.
   PubMedGoogle Scholar
• OLSSON B: Aerosol particle generation from dry powder inhalers - can they equal pressurized metered dose inhalers?' Aerosol Med. (1995) 8\(Suppl. 3):513–519.
   Google Scholar
• THORSSON L, EDSBACKER S, KALLEN A, LOFDAHL C-G: Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br. J. Clin. Pharmacol (2001) 52:529–538.
   PubMed Web of Science ®Google Scholar
• DERENDORF H, HOCHLAUS G, MEIBOHM B, MOLLMANN H, BARTH J: Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J. Allergy Clin. brimunol. (1998) 101(4 Pt 2):S440–S446.
   Google Scholar
• EDSBACKER S, ANDERSSON P, LINDBERG C, RYRFELDT A, THALEN A: Metabolic acetal splitting of budesonide. A novel inactivation pathway for topical glucocorticoids. Drug Metal,. Dispos. (1987) 15:412–417.
   PubMedGoogle Scholar
• JONSSON G, ASTROM A, ANDERSSON P: Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metal,. Dispos. (1995) 23:137–142.
   PubMed Web of Science ®Google Scholar
• KAISER H, AARONSON D, DOCKHORN R, EDSBACKER S, KORENBLAT P, KALLEN A: Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler®. Br: J. Clin. Pharmacol (1999) 48:309–316.
   PubMed Web of Science ®Google Scholar
• SUMMARY OF PRODUCT CHARACTERISTICS: Symbicort. AstraZeneca UK Ltd (2002).
   Google Scholar
• KEMP JP, SKONER DP, SZEFLER SJ, WALTON-BROWN K, CRUZ-RIVERA M, SMITH JA: Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann. Allergy Asthma Immunol (1999) 83:231–239.
   PubMed Web of Science ®Google Scholar
• AKPINARLI A, TURNER A, SARACLARY, SEKEREL BE, KALAYCI 0: Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Arch. Dis. Child (1999) 81:45–48.
   PubMed Web of Science ®Google Scholar
• BENSCH G, BERGER WE, BLOKHIN BM et al.: One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann. Allergy Asthma Immunol (2002) 89:180–190.
   PubMed Web of Science ®Google Scholar
• LALLOO UG, MALOLEPSZY J, KOZMA D et al: Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroids in adults with mild-to-moderate asthma. Chest (2003) 123:1480–1487.
   PubMed Web of Science ®Google Scholar
• TAL A, SIMON G, VERMEULEN JH et al.: Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr. Pulmonol (2002) 34:342–350.
   PubMed Web of Science ®Google Scholar
• BATEMAN ED, BANTJE TA, GOMES MJ et al.: Budesonide/formoterol in a single inhaler is more effective than fluticasone in moderate persistent asthma. Am. J. Respir. Med. (2003) 2:275–281.
   PubMedGoogle Scholar
• CREEMERS JPHM, BANTJE TA, ELIRAZ A, EKSTROM T, BUHL R: Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate, persistent asthma. Eur: Respir: .1. (2002) 20\(Suppl. 38):S387.
   Google Scholar
• BUHL R, CREEMERS JPHM, VONDRA V, MARTELLI NA, NAYA IP, EKSTROM T: Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir. Med. (2003) 97:323-330. A clinical study demonstrating the efficacy of once-daily dosing of budesonide/formoterol.
   Google Scholar
• KUNA P, CHURCHALIN A, RINGDAL N et al.: Low dose single-inhaler budesonide/formoterol administered once-daily is effective in mild asthma. Eur. Respir. (2001) 18\(Suppl. 33):5158.
   Google Scholar
• VAN DER WOUDE HJ, BOORSMA M, BERGQVIST PBF et al: More rapid relief of methacholine-induced bronchoconstriction with budesonide/formoterol than salmeterol/fluticasone. Eur. Respir. (2001) 18\(Suppl. 33):S53.
   Google Scholar
• VAN DER WOUDE HJ, BOORSMA M, BERGQVIST PBF, AALBERS R: Symbicort® produces relief of dyspnoea in one minute. Am. J. Respir. Grit. Care Med. (2002) 165(Suppl.):A567.
   Google Scholar
• PALMQVIST M, IBSEN T, MELLEN A, LOTVALL J: Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. (1999) 160:244–249.
   PubMed Web of Science ®Google Scholar
• FOREST A, MORELLI MC, CATENA E: Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. The Italian Study Group. Chest (2000) 117:440-446. A clinical study demonstrating that additional and frequent (q.i.d.) doses of budesonide at the onset of an asthma exacerbation were beneficial.
   Google Scholar
• TATTERSFIELD AE, LOFDAHL C-G, POSTMA DS et al: Comparison of formoterol and terbutaline in moderate asthma. Am. J. Respir: Crit. Care Med. (1999) 159:A636.
   Google Scholar
• IND P, HAUGHNEY J, PRICED, ROSEN J-P, KENNELLY J: Managed adjustable dosing of budesonide/formoterol combination provides equivalent asthma control to fixed dosing at a lower overall dose. Eur: Respir: (2002) 20\(Suppl. 38):S396-S397. A randomised, clinical study showing that adjustable dosing with budesonide/formoterol is as effective as fixed dosing, despite a lower overall drug load.
   Google Scholar
• IND P, HAUGHNEY J, PRICED, ROSEN J-P, KENNELLY J: 4-month adjustable or fixed maintenance treatment with budesonide/formoterol in a single inhaler reduced symptom severity. Ear. Respic (2002) 20\(Suppl. 38):541.
   Google Scholar
• IND P, HAUGHNEY J, ROSEN J-P, KENNELLY J: Managed adjustable dosing of budesonide/formoterol combination is similarly well tolerated to fixed dosing. Ear. Respic (2002) 20\(Suppl. 38):542.
   Google Scholar
• PRICE D, HAUGHNEY J, HUTCHINSON J, LLOYD A, PLUMB J: Budesonide/formoterol with an adjustable maintenance plan costs less and is as effective as fixed dosing. Ear. Respic (2002) 20\(Suppl. 38):5397.
   Google Scholar
• HAUGHNEY J, PRICE D, ROSEN J-P, KENNELLY J: Adjustable maintenance treatment with budesonide/formoterol combination rapidly improves and maintains quality of life in asthma patients. Ear: Respir. (2002) 20\(Suppl. 38):541–542.
   Google Scholar
• OLSSON P, STALLBERG B, EKSTROM T, LINDARCK N, JORGENSEN LA: Adjustable maintenance treatment of asthma with budesonide and formoterol in a single inhaler. Ear. Respic (2002) 20\(Suppl. 38):5397.
   Google Scholar
• •Further evidence that budesonide/formoterol adjustable maintenance dosing provides better asthma control than traditional fixed dosing regimens.
   Google Scholar
• BUHL R, KARDOS P, BAARE A et al: Symptom-guided adjustable dosing asthma therapy with budesonide and formoterol in a single inhaler - the ATACO study. J. Allergy Clin. Innnunol. (2003) 111:S127.
   Google Scholar
• ROSENHALL L, ERICSSON K, BORG S, ANDERSSON F: Healthcare costs are reduced when asthma is treated with budesonide and formoterol in a single inhaler compared with the same medication via separate inhalers. Ear. Respic (2001) 18\(Suppl. 33):S54.
   Google Scholar
• ROSENHALL L, BORG S, ANDERSSON F, ERICSSON K: Budesonide/formoterol in a single inhaler (Symbicort9 reduces healthcare costs in the long-term treatment of asthma compared with separate inhalers. Int. Clin. Pract. (In Press).
   Google Scholar
• AGERTOFT L, PEDERSEN S: Effect oflong-term treatment with inhaled budesonide on adult height in children with asthma. N Engl. I Med. (2000) 343:1064–1069.
   PubMed Web of Science ®Google Scholar
• •The best study on the long-term side effects of inhaled corticosteroids in children with asthma.
   Google Scholar
• SCHREURS AJ, SINNINGHE DAMSTE HE, DE GRAAF CS, GREEFHORST AP: A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients. Ear. Respic (1996) 9:1678–1683.
   PubMed Web of Science ®Google Scholar
• MEYER RJ: Supplemental new drug application for changes to the pregnancy subsection of the precautions section related to a change in the pregnancy category for Pulmicort Turbuhaler® 'C' to 'B'. AstraZeneca LP US Food and Drug Administration, Department of Health and Human Services (2001).
   Google Scholar
• LOT VALL J, PERSSON G, LARSSON P, MARDELL C, ROSENBORG J: Tolerability of inhaled high doses of formoterol and salbutamol in asthmatic patients maintained on twice-daily formoterol 12 lig (9 lig delivered). Ear. Respir. (1997) 19\(Suppl. 25):5103.
   Google Scholar
• ROSENBORG J, BENGTSSON T, LARSSON P, BLOMGREN A, PERSSON G, LOTVALL J: Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Ear. Clin. Pharmacol. (2000) 56:363–370.
   PubMed Web of Science ®Google Scholar
• IND P, BORSZORMENYI NAGY G, PIETINALHO A et al.: Formoterol 4.5 µg, used as needed via Turbuhaler was as safe and well tolerated as terbutaline 0.5 mg. Ear. Respir. (1999) 14\(Suppl. 30):5148.
   Google Scholar
• TATTERSFIELD A, LOFDAHL C-G, POSTMA DS et al.: Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet (2001) 357:257–261.
   PubMed Web of Science ®Google Scholar
• MALOLEPSZY J, BOSZORMENYI NAGY G, SELROOS 0, LARSSO P, BRANDER R: Safety of formoterol Turbuhaler® at cumulative dose of 90 pg in patients with acute bronchial obstruction. Ear: Respic J. (2001) 18:928–934.
   PubMed Web of Science ®Google Scholar
• ROSENHALL L, HEINIG JH, LINDQVIST A, LEEGAARD J, STAHL E, BERGQVIST PB: Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. Int. J. Clin. Pract. (2002) 56:427–433.
   PubMed Web of Science ®Google Scholar
• •The most comprehensive study of the safety of budesonide/formoterol so far.
   Google Scholar
• ROSENHALL L, STAHL E, HENIG JH, LINDQVIST A, LEEGARD J, BERGQVIST PBF: Health-related quality of life and asthma control in patients treated with budesonide and formoterol in a single inhaler. Ear. Respic J. (2001) 18\(Suppl. 33):545.
   Google Scholar
• ANKERST J, PERSSON G, WEIBULL E: Tolerability of high cumulative doses of budesonide/formoterol single inhaler in patients with asthma. Puhn. Pharmacol. Ther. 16(3):147–151.
   Google Scholar
• •A clinical study showing that high doses of budesonide/formoterol are well tolerated.
   Google Scholar
• SZAFRANSKI W, CUKIER A, RAMIREZ A et al.: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Ear: Respic J. (2003) 21:74–81.
   PubMed Web of Science ®Google Scholar